Pregmune is a specialized healthcare startup focused on reproductive immunology, helping individuals and couples facing fertility challenges. The company offers a unique service called the Pregmune PGM 1 Reproductive Immunology Assessment Report. This report aims to identify immunological causes behind infertility, miscarriages, and failed IVF (In Vitro Fertilization) cycles, including those using donor eggs. By pinpointing these causes, Pregmune helps minimize the financial and emotional toll of repeated, costly, and often unsuccessful fertility treatments.

Pregmune primarily serves individuals and couples who have been trying to conceive for over a year without success, those who have experienced miscarriages, or those who have had failed IVF cycles. The company operates in the fertility healthcare market, which includes reproductive endocrinologists, OB-GYNs, and primary care physicians.

The business model is based on providing personalized reproductive immunology assessments. Clients, through their physicians, request a consultation with Pregmune. The company then conducts a series of lab tests, which are reviewed, validated, and interpreted by Pregmune's medical and research team. The results are compiled into the PGM 1 report, which is sent to the client's physician. The physician then uses this report to tailor a fertility treatment plan based on Pregmune's recommendations.

Pregmune generates revenue by charging for these specialized immunology assessments. The cost is typically covered by the clients or their insurance, depending on their coverage plans. This model ensures a steady stream of income while providing valuable insights that can lead to more successful fertility treatments.

Keywords: fertility, immunology, infertility, miscarriages, IVF failures, personalized care, reproductive health, lab tests, healthcare startup, fertility treatments.